Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty

@article{Anderson2013AspirinVL,
  title={Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty},
  author={David R Anderson and Michael J. Dunbar and Eric Bohm and Etienne L. Belzile and Susan R. Kahn and David J. Zukor and William Fisher and Wade T Gofton and Peter L. Gross and St{\'e}phane Pelet and Mark Andrew Crowther and Steven J MacDonald and Paul Kim and Susan Pleasance and Nicki Davis and Pantelis Andreou and Philip Stephen Wells and Michael J. Kovacs and Marc Alan Rodger and Tim Ramsay and Marc Carrier and Pascal-Andr{\'e} Vendittoli},
  journal={Annals of Internal Medicine},
  year={2013},
  volume={158},
  pages={800 - 806}
}
BACKGROUND The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. OBJECTIVE To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. DESIGN Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0%. Randomization was electronically generated; patients were assigned to a treatment group through a Web-based… 
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial
TLDR
The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients, and LMWH demonstrated a 60.5% VTE Prevention benefit in the weighted time to event analysis.
Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty
TLDR
This article adds useful information on the role of aspirin in the orthopedic setting and the generalizability of the findings is probably questionable given the recent availability of novel oral anticoagulants for VTE prophylaxis after hip replacement.
Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty
TLDR
This article adds useful information on the role of aspirin in the orthopedic setting and the generalizability of the findings is probably questionable given the recent availability of novel oral anticoagulants for VTE prophylaxis after hip replacement.
Inpatient compliance with venous thromboembolism prophylaxis after orthopaedic trauma: results from a randomized controlled trial of aspirin versus low molecular weight heparin
TLDR
These data should reassure clinicians that inpatient compliance is similar for low molecular weight heparin and aspirin regimens, as well as reassure patients that venous thromboembolism prophylaxis regimens are safe.
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
TLDR
Aspirin and factor Xa inhibitors provided improved DVT prophylaxis with lower rates of postoperative anaemia compared to enoxaparin and warfarin and the utilisation of aspirin and factorXa inhibitors increased over time.
Evaluation of Pharmacologic Strategies for Prevention of Venous Thromboembolism in Elective Orthopedic Surgery
TLDR
There has been an increase in the use of aspirin at a tertiary academic medical center in postoperative orthopedic surgery patients withoutAn increase in DOAC use and no difference was detected in safety and efficacy endpoints in warfarin versus aspirin patients.
Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis
TLDR
This study demonstrates that low-dose aspirin is not inferior to high- dose aspirin for venous thromboembolism prophylaxis following total joint arthroplasty and is associated with fewer gastrointestinal side effects.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
TLDR
A systematic review is performed to provide clinicians with a practical pathway for translating clinical research into practice and suggest a need for extended out-of-hospital prophylaxis in patients undergoing total-hip replacement but not for patients undergoingtotal-knee replacement.
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
TLDR
There were significantly fewer venous thromboembolic complications in patients undergoing elective hip replacement when prophylaxis with enoxaparin was given for a total of one month, rather than only during the hospitalization.
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review.
TLDR
The absolute reduction in symptomatic venous thromboembolism attributed to extended prophylaxis in some studies and meta-analyses seems to have been overestimated.
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
TLDR
Extended dalteparin prophylaxis resulted in significantly lower frequencies of deep vein thrombosis compared with in-hospital warfarin therapy, and will lessen the burden to both the patient and society.
The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry.
TLDR
The results should be considered when the conflicting recommendations of existing guidelines for thromboprophylaxis after hip replacement are being addressed.
Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
TLDR
Prolonging enoxaparin thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of venous thromboembolism, without compromising safety.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
TLDR
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once- daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty.
...
1
2
3
4
...